Form 8-K - Current report:
SEC Accession No. 0001641489-24-000069
Filing Date
2024-10-25
Accepted
2024-10-25 16:29:55
Documents
13
Period of Report
2024-10-22
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K vtvt-20241022.htm   iXBRL 8-K 22690
  Complete submission text file 0001641489-24-000069.txt   144916

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtvt-20241022.xsd EX-101.SCH 1794
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtvt-20241022_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtvt-20241022_pre.xml EX-101.PRE 12516
16 EXTRACTED XBRL INSTANCE DOCUMENT vtvt-20241022_htm.xml XML 2829
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

EIN.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37524 | Film No.: 241397421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)